Sugi Predict

Sugi Predict / Compounds / SCHEMBL772902

SCHEMBL772902

SCHEMBL772902

Brc1ccccc1CCOC1CCCCO1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 1/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ KCNA5 P22460 1/20 0.39
▸ SCN5A Q14524 1/20 0.39
▸ TAAR1 Q96RJ0 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ TACR1 P25103 1/20 0.36
▸ CYP2A13 Q16696 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23043224 0.85 KDM4C (0.51) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL2006340 0.85 TACR1 (0.45) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL6097349 0.85 KDM4C (0.44) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL6095923 0.84 MEN1 (0.44) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL2649803 0.84 KDM4C (0.52) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL6632939 0.84 KDM4C (0.44) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL6097200 0.84 KDM4C (0.44) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL6096051 0.84 KDM4C (0.44) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL7690214 0.83 KDM4C (0.53) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL10679113 0.83 KDM4C (0.53) KDM4CL3MBTL1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 — — US disclosed
CN-114615981-B KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2024-04-12 — — CN disclosed
US-20230077225-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
US-11453683-B1 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2022-09-27 — — US disclosed
EP-4021444-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-07-06 — — EP disclosed
CN-114615981-A KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2022-06-10 — — CN disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
EP-1719773-B1 FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC (JP) 2009-04-15 — — EP disclosed
EP-1719773-B1 FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC (JP) 2009-04-15 — — EP disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 — — US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 — — US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 — — US disclosed
EP-1719773-A1 FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR Japan Tobacco, Inc. (JP) 2006-11-08 — — EP disclosed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 — — EP disclosed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 — — WO disclosed
US-20020188018-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GONG LEYI (US) 2002-12-12 — — US disclosed
US-20020052397-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta SYNTEX (U.S.A.) LLC 2002-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 KDM4C 1894/4885L3MBTL1 4435/4885NPC1 1131/4885
US-20230077225-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS KDM4C 4005/4885L3MBTL1 2705/4885NPC1 1523/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS KDM4C 4067/4885L3MBTL1 3074/4885NPC1 2476/4885
US-20020052397-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GSK3B, GSK3A, PYGL KDM4C 2961/4885L3MBTL1 4570/4885NPC1 3465/4885
US-20020188018-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GSK3B, GSK3A, PYGL KDM4C 1889/4885L3MBTL1 4448/4885NPC1 3628/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS KDM4C 4422/4885L3MBTL1 3390/4885NPC1 1237/4885
US-11453683-B1 KRas G12D inhibitors KRAS, NRAS, HRAS KDM4C 4439/4885L3MBTL1 3454/4885NPC1 1236/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS KDM4C 4005/4885L3MBTL1 2705/4885NPC1 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.